Raise your Query
Hi! Simply click below and type your query.
Our experts will reply you very soon.
Hi! Simply click below and type your query.
Our experts will reply you very soon.
| Business Type | Supplier, Retailer, Wholesaler |
| Composition of Product | Cefepime 1000 mg+ Tazobactum 125 mg |
| Form | Injection |
| Pack Type | Vial with SWFI |
| Click to view more | |
Preferred Buyer From
| Location | Worldwide |
Product Details
Cefepime 1000mg + Tazobactam 125mg Salt Information :
Uses of Cefepime 1000mg + Tazobactam 125mg:
Cefepime is a broad spectrum antibiotic used in various baterial infections like gastritis , pneumonia , urinary tract infections and kidney infections .
Side Effects of Cefepime 1000mg + Tazobactam 125mg:
Positive Coombs' test without haemolysis; rash, pruritus; diarrhoea, nausea, vomiting; fever, headache; pain and erythema at inj site; agranulocytosis; anaphylactic shock; leucopenia; neutropenia; thrombocytopenia.
Drug Interactions of Cefepime 1000mg + Tazobactam 125mg:
Increased effect with high-dose probenecid; increased nephrotoxic potential with aminoglycosides.
Contraindications of Cefepime 1000mg + Tazobactam 125mg:
Hypersensitivity to cefepime or other cephalosporins.
Mechanism of Action of Cefepime 1000mg + Tazobactam 125mg:
Cefepime is a 4th generation cephalosporin which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall by binding to one or more of the penicillin-binding proteins (PBPs). Absorption: IM admin: Rapid and almost complete absorption. Distribution: 16-19% bound to plasma proteins. Volume of distribution: 14-20 L; crosses the blood brain barrier. Penetrates into inflammatory fluid at concentrations of about 80% of serum levels. Metabolism: Minimally hepatic. Excretion: Plasma half-life: 2 hr. Excreted in urine with 85% as unchanged drug.
Special Precautions for Cefepime 1000mg + Tazobactam 125mg:
Renal impairment; history of penicillin or cephalosporin allergy; lactation, pregnancy. Caution when used in patients with history of GI diseases, especially colitis. May decrease prothrombin activity; monitor prothrombin time in patients with poor nutritional state, renal or hepatic impairment and those on prolonged treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms, resulting in superinfection. Consider the possibility of Clostridium difficile associated diarrhoea in patients who present with diarrhoea after treatment. Caution when used in patients with a history of seizures.
